TrianglePembrolizumab (NCT06123338)
Pembrolizumab trial for Esophageal Cancer (NCT06123338). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated HER2-positive esophageal, gastroesophageal-junction or gastric adenocarcinoma that can be completely removed by surgery. Metastatic and recurrent disease are excluded.
The idea: combine surgery and chemotherapy with trastuzumab, which targets HER2-bearing cells, and pembrolizumab, which releases an immune brake. Chemotherapy uses fluorouracil, oxaliplatin and docetaxel; earlier participants received a different doublet. Eight chemotherapy-containing cycles surround surgery, followed by the two antibodies to complete one treatment year. Researchers track recurrence, progression and survival.
This phase 2 study plans 49 patients. Yelena Janjigian leads MSK; nine US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.